Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure
- 29 August 2017
- journal article
- review article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 23 (3) , 481-497
Abstract
Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of catecholamines due to sympathoadrenal activation. Focus is now shifting from merely glycemic control to multifactorial approach. In the context of individual drugs and classes, this article reviews interdisciplinary strategies evaluating metabolic effects of drugs for treatment of chronic heart failure (CHF) which can mask characteristic hypoglycemia symptoms. Hypoglycemia unawareness and cardiac autonomic neuropathy are discussed. Data suggesting that hypoglycemia modulates immune response are reviewed. The potential role of gut microbiota in improving health of patients with diabetes and CHF is emphasized. Reports stating that nondiabetic CHF patients can have life-threatening hypoglycemia associated with imbalance of thyroid hormones are discussed. Regular glycemic control based on HbA1c measurements and adequate pharmacotherapy remain the priorities in diabetes management. New antihyperglycemic drugs with safer profiles should be preferred in vulnerable CHF patients. Multidrug interactions must be considered. Emerging therapies with reduced hypoglycemia risk, telemedicine, sensor technologies, and genetic testing predicting hypoglycemia risk may help solving the challenges of hypoglycemia in CHF patients with diabetes. Interdisciplinary work may involve cardiologists, diabetologists/endocrinologists, immunologists, gastroenterologists, microbiologists, nutritionists, imaging specialists, geneticists, telemedicine experts, and other relevant specialists. This review emphasizes that systematic knowledge on pathophysiology of hypoglycemia in diabetic patients with CHF is largely lacking and the gaps in our understanding require further discoveries.Keywords
Funding Information
- Russian Science Foundation (17-15-01111)
- Ministry of Education and Science of the Russian Federation (4.8192.2017)
This publication has 162 references indexed in Scilit:
- Type 1 diabetes and cardiovascular diseaseCardiovascular Diabetology, 2013
- Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculationCardiovascular Diabetology, 2013
- Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic controlCardiovascular Diabetology, 2012
- The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD StudyDiabetes Care, 2012
- Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart FailureCirculation: Heart Failure, 2011
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failureCardiovascular Diabetology, 2010
- Repeated Episodes of Hypoglycemia as a Potential Aggravating Factor for Preclinical Atherosclerosis in Subjects With Type 1 DiabetesDiabetes Care, 2010
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive ratsCardiovascular Diabetology, 2010
- Anti-Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or GlyburideClinical Pharmacology & Therapeutics, 2010
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008